
Results 1 - 20 of 665 in Chronic Pain
New Neurostimulation Patient Programming Software Enables More...
... Technology software for Rapid Programmer, a programming platform used to optimize neurostimulation therapy for chronic pain patients. Introduced at the North American Neuromodulation Society annual meeting, this new software is designed to help ... Comment?
Love Hurts: Why Emotional Pain Really Affects Us
... D from the sun's ultraviolet rays, so it's known as the sunshine vitamin... Latest Videos for Pain Treating Chronic Pain Chronic pain is pain that continues past the normal healing time for an injury. Learn about the causes and current treatment ... Comment?
... and members of advocacy groups who say medical marijuana should be legal because it is effective in treating chronic pain, nausea and other ailments. The bill is sponsored by state Rep. Mark Cohen, D-Philadelphia. It is not given much of a chance to ... Comment?
The Effects of Long-Term Painkiller Therapy
... or more) to back them up. Enter Forest Tennant, MD, who undertook a first-of-its-kind research study evaluating chronic pain patients who had been receiving opioid therapy for 10 to 35 years. The results of his study should be extremely encouraging ... Comment?
Highly Involved Patients Less Willing To Undergo Risky Treatments
w/Photo
... of the Yale study were told about hypothetical new medications that would either prevent heart disease or treat chronic pain. These hypothetical treatments were said to be very effective, well tolerated and covered by insurance, but participants ... Comment?
... ors and members of advocacy groups who say medical marijuana should be legal because it's effective in treating chronic pain and nausea. Comment?
PA Holds Hearings On Rx Marijuana
... ors and members of advocacy groups who say medical marijuana should be legal because it's effective in treating chronic pain and nausea. Comment?
Medical marijuana bill gets hearing
... and members of advocacy groups who say medical marijuana should be legal because it is effective in treating chronic pain, nausea and other ailments. However, the bill, sponsored by Rep. Mark Cohen, D-Philadelphia, faces long odds because it is ... Comment?
Pa. bill to allow medical marijuana gets hearing
... and members of advocacy groups who say medical marijuana should be legal because it is effective in treating chronic pain, nausea and other ailments. However, the bill, sponsored by Rep. Mark Cohen, D-Philadelphia, faces long odds, because it is ... Comment?
Bill To Allow Medical Marijuana Gets Hearing In Pa.
... and members of advocacy groups who say medical marijuana should be legal because it is effective in treating chronic pain, nausea and other ailments. However, Pennsylvania House Bill 1393 , sponsored by Philadelphia County Rep. Mark Cohen , ... Comment?
Bill to Allow Medical Marijuana Gets Hearing
... and members of advocacy groups who say medical marijuana should be legal because it's effective in treating chronic pain and nausea. However, a bill sponsored by Philadelphia Democrat Mark Cohen faces long odds in the Legislature. A spokesman says ... Comment?
Pa. House committee hears testimony on medical marijuana bill
... and members of advocacy groups who say medical marijuana should be legal because it is effective in treating chronic pain, nausea and other ailments. However, the bill, sponsored by Rep. Mark Cohen, D-Philadelphia, faces long odds, because it is ... 6 comments
... in our state. Discussing the pros and cons of prescription pot, used in several other states as a way to treat chronic pain. It was a small step for the legislation but a big step for advocates of the drug. Hb1393 is also called the compassionate ... Comment?
Pa. Lawmakers Hear Testimony For Medical Marijuana
... and members of advocacy groups who say medical marijuana should be legal because it's effective in treating chronic pain and nausea. However, a bill sponsored by Philadelphia Democrat Mark Cohen faces long odds in the Legislature. A spokesman says ... Comment?
Patients Say 'No Thanks' to Risky Medical Treatments
... where patients have the rare risk of developing jaw necrosis. Video B described a new medication to treat chronic pain where there was a risk of progressive multifocal leukoencephalopathy relevant to patients with rheumatic diseases. Participants ... Comment?
Neuros Medical to Present Poster at 13th Annual North American Neuromodulation Society Meeting
Neuros Medical, Inc., a medical device company developing innovative neurostimulation technology for the treatment of chronic pain, announced they will present a poster on clinical applications at the upcoming North American Neuromodulation Society 13th Annual Meeting this week in Las Vegas, Nevada. Comment?
Patients Say No To Risky Medical Treatments
... where patients have the rare risk of developing jaw necrosis. Video B described a new medication to treat chronic pain where there was a risk of progressive multifocal leukoencephalopathy relevant to patients with rheumatic diseases. Participants ... Comment?
Millennium Laboratories Announces National Pain Management Services...
Millennium Laboratories , a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today an agreement with Three Rivers Provider Network , the largest and fastest growing proprietary Preferred Provider Organization network in the United States. Comment?
Adolor Corporation Initiates Clinical Testing In Opioid Bowel Dysfunction Program
... persistent pain such as pain associated with, or as a result of, back pain, arthritis and other chronic pain conditions. However, the use of opioids is associated with gastrointestinal (GI) side effects such as constipation , abdominal pain and ... Comment?
Given A Choice, Arthritis Patients Take More Conservative Clinical Approach
... where patients have the rare risk of developing jaw necrosis. Video B described a new medication to treat chronic pain where there was a risk of progressive multifocal leukoencephalopathy relevant to patients with rheumatic diseases. Participants ... Comment?